Myelofibrosis Treatment in Turkey
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is Myelofibrosis?
Myelofibrosis is a chronic blood cancer and myeloproliferative neoplasm in which abnormal blood-forming cells and changes in the bone marrow environment cause progressive bone marrow fibrosis. As normal blood-cell production declines, patients may develop anaemia, low platelet counts, or abnormal white blood-cell counts. The spleen and liver may begin producing blood cells outside the bone marrow, which can enlarge these organs. Myelofibrosis may develop on its own as primary myelofibrosis or occur after another myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia.
What is the Importance of Timely Treatment?
Timely diagnosis and risk assessment are important because myelofibrosis can progress differently from one person to another. Some patients have stable disease and require regular monitoring, while others develop significant anaemia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms, or progression to an advanced phase of disease. Early specialist assessment helps determine disease risk, monitor blood counts and symptoms, manage complications, and identify patients who may be candidates for potentially disease-modifying treatment such as allogeneic stem-cell transplantation.
What are the Common Symptoms of Myelofibrosis?
- Persistent fatigue and weakness
- Shortness of breath, particularly with activity
- Pale skin due to anaemia
- Unexplained weight loss
- Fever or night sweats
- Loss of appetite
- Bone or muscle pain
- Abdominal fullness or discomfort due to an enlarged spleen
- Feeling full after eating a small amount
- Easy bruising or bleeding
- Frequent infections in some patients
- Itching
- Reduced exercise tolerance
Causes and Risk Factors of Myelofibrosis
Causes
- Myelofibrosis develops when abnormal blood-forming stem or progenitor cells acquire genetic changes that promote uncontrolled or abnormal blood-cell production and release inflammatory signals that alter the bone marrow environment.
- Mutations in genes such as JAK2, CALR, and MPL are commonly associated with myelofibrosis, although some patients lack these driver mutations.
- Primary myelofibrosis develops independently, while secondary myelofibrosis can develop after polycythemia vera or essential thrombocythemia.
Risk Factors
- Increasing age
- Presence of an underlying myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia
- Certain acquired genetic mutations
- Previous treatment or disease-related factors associated with secondary myelofibrosis
- Certain adverse molecular or cytogenetic features associated with higher-risk disease
Latest Research and Technologies in the Treatment of Myelofibrosis in Turkey
- Current myelofibrosis research focuses on improving symptom and spleen control, treating anaemia, and developing therapies that may alter disease progression. JAK inhibitors remain an important targeted treatment approach, while newer and investigational therapies are being studied for patients with anaemia, thrombocytopenia, inadequate response or intolerance to existing treatments. Clinical research is also evaluating combinations of targeted therapies and JAK inhibitor approaches alongside allogeneic hematopoietic stem-cell transplantation.
Treatment options for Myelofibrosis
Stem-Cell Transplantation : Allogeneic hematopoietic stem-cell transplantation is a potentially disease-modifying treatment and may be considered for selected patients with higher-risk disease who are medically suitable for transplantation. Pre-transplant disease control and donor selection are important parts of treatment planning.
Cost Start From 20000Explore Options
Supportive and palliative care: Symptom management, nutritional support and psychological support can help maintain quality of life throughout treatment.
Targeted treatment: Medicines that act on pathways involved in myelofibrosis may help reduce an enlarged spleen and improve symptoms in suitable patients.
- Clinical assessment:
- Medical and Hematological Evaluation: A detailed history is taken to assess fatigue, weight loss, fever, night sweats, abdominal discomfort, bleeding, infections, bone pain and other constitutional symptoms.
- Complete Blood Count and Peripheral Blood Assessment: A peripheral blood smear may show characteristic abnormalities, such as immature blood cells or teardrop-shaped red blood cells, and can provide additional information about abnormal blood-cell production.
- Bone Marrow Evaluation: Bone marrow aspiration and biopsy are central to diagnosing myelofibrosis. The biopsy evaluates the degree and pattern of bone marrow fibrosis, abnormal megakaryocytes and other marrow changes.
- Molecular and Cytogenetic Assessment: Cytogenetic testing can identify chromosomal abnormalities and may help assess risk.
- Risk and Prognostic Assessment: Doctors assess clinical, laboratory, cytogenetic and molecular features to estimate disease risk and guide treatment decisions.
- Imaging Tests:
- Abdominal Ultrasound: Helps assess spleen and liver size and can monitor splenomegaly.
- CT Scan: Provides a more detailed assessment of the spleen, liver, lymph nodes, and abdominal structures when needed.
- MRI: May be used selectively to evaluate bone marrow or other areas when additional structural information is needed.
- PET/CT: May be considered in selected situations when extramedullary disease or another complication requires further evaluation.
- Imaging for Treatment Monitoring: Ultrasound or CT may monitor changes in spleen size during treatment.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive tele-rehabilitation services designed to support Myelofibrosis patients in Turkey. These services include:
- Physical Activity and Exercise: Individually tailored physical activity can help maintain muscle strength, endurance, and mobility, with intensity adjusted based on anaemia, platelet levels, fatigue, and overall health.
- Nutritional Support: Dietitians can provide personalised nutrition guidance to support adequate calorie and protein intake, manage appetite loss, and address nutritional deficiencies or treatment-related needs.
- Fatigue Management: Structured activity planning, adequate rest, energy-conservation techniques and treatment of underlying anemia can help patients manage persistent fatigue.
- Functional Rehabilitation: Patients with weakness, reduced exercise tolerance, pain or prolonged hospitalisation may benefit from physiotherapy and occupational therapy to maintain independence.
- Psychological and Long-Term Support: Counselling, patient education and support programmes can help patients cope with a chronic blood cancer, treatment-related stress and the need for long-term monitoring or transplantation.
- Clinicians select medicines for myelofibrosis based on symptoms, spleen enlargement, anaemia, platelet counts, disease risk, and prior treatment. JAK inhibitors may reduce disease-related symptoms and splenomegaly in appropriate patients. Anaemia treatment may include red-blood-cell transfusions, erythropoiesis-supporting medicines, or other selected therapies depending on the underlying cause and clinical circumstances. Additional medicines may manage infections, bleeding, pain, constitutional symptoms or other complications.
Instantly Connect with our Specialists
Hospitals for Myelofibrosis in Turkey
Medstar Antalya Hospital
Ankara, Turkey
- Medstar Antalya Hospital has been providing patients with modern medical services since 2009.
- It is part of the trusted Memorial Health Group, which is known for expert healthcare in Turkey.
- The hospital is situated on a large campus and features advanced medical equipment and facilities.
- It has 124 comfortable beds for patients and five fully prepared operating rooms for surgeries.
- There are 33 intensive care beds, including specialised units for newborns who require additional support.
- The hospital treats many health issues like cancer, heart problems, brain conditions, and more.
- Modern machines, such as MRI, CT, and PET-CT, help doctors identify and treat problems quickly and safely.
- Medstar meets international safety and care standards and is trusted by both local and global patients.
- Care plans are made specially for each person, and emotional well-being is also supported.
- Its location in Antalya makes it easy to reach and ideal for people coming from other countries for treatment.
Guven Hospital
Ankara, Turkey
Started as a small hospital and has become a large general Hospital with-
- 254 beds
- 12 Operating rooms
- Staff of 1600 people including expert physicians, nurses, and auxiliary health personnel
- Guven Medical Surgical Centre
- IVF Centre
- Blood Bank
- Organ Transplant Centre
- Fully-equipped centres to perform various types of Surgeries
- Guven Healthy Living Campus for patients
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose Turkey for Myelofibrosis Treatment?
- Multidisciplinary Haematology Care: Patients can access haematologists, hemato-oncologists, transfusion specialists, transplant physician,s and supportive-care teams based on their clinical needs.
- Advanced Diagnostic Facilities: Specialised centres may provide bone marrow biopsy, molecular testing for myelofibrosis-associated mutations, cytogenetic analysis and advanced imaging.
- Targeted Treatment Options: Eligible patients may receive modern JAK-inhibitor therapy and supportive treatments based on disease characteristics and blood counts.
- Stem-Cell Transplantation: Major transplant centres can evaluate suitable patients for allogeneic hematopoietic stem-cell transplantation, including donor assessment and post-transplant monitoring.
- Comprehensive Support and International Patient Services: The treatment pathway can include blood transfusion support, nutritional counselling, rehabilitation, follow-up care, and international patient coordination.
Frequently Asked Questions
Author
Pragun Gupta
Pragun Gupta is a Doctor of Pharmacy (Pharm. D.) professional from Teerthanker Mahaveer University with hands-on experience in clinical pharmacology, clinical research, and evidence-based medical writing. Through her clinical and research exposure, she has developed a strong interest in pharmacoeconomics, pharmacology, therapeutics, and pharmacovigilance.
As a medical writer, she works on medical and scientific research articles, patient education materials, and healthcare-focused content. Her clinical research and evidence-based writing experience enables her to translate complex medical information into clear, accurate, patient-friendly content while maintaining scientific credibility and medical accuracy. Her primary aim is to make healthcare information accessible and easy for patients and general readers to understand.
View MoreReviewer
Dr. Akash Khandelwal
Hematologist
9 Years of Experience
Dr. Akash Khandelwal is a distinguished Hematologist, Hemato-oncologist, and Bone Marrow Transplant (BMT) Physician with extensive training from the prestigious AIIMS New Delhi. His expertise encompasses a wide range of specialized techniques in bone marrow transplantation, including autologous and allogeneic transplants such as matched sibling donors, matched unrelated donors (MUD), and haploidentical donor transplants. Dr. Khandelwal has personally supervised and conducted over 100 bone marrow transplants. View More
Last Reviewed - January 2026